Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB

Bibliographic Details
Published in:	Pulmonology
Main Authors:	A. Oehadian, M.L. Bastos, R. Centis, L. D'Ambrosio, G.B. Migliori, P. Santoso, R. Ruslami, D. Menzies
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-03-01
Online Access:	https://www.tandfonline.com/doi/10.1016/j.pulmoe.2023.09.003

Similar Items

Beyond a cure for TB: confronting the hidden burden of post-TB lung disease
by: Y. Kherabi, et al.
Published: (2025-05-01)

Long-term sequelae of TB and COVID-19 co-infection: Prospective cohort evaluation after 1 year
by: D.R. Silva, et al.
Published: (2023-11-01)

Multidrug-resistant tuberculosis today
by: A Matteelli, et al.

Multidrug-resistant tuberculosis today
by: A Matteelli, et al.
Published: (2012-02-01)

Visual Recovery Following Linezolid Cessation in an MDR-TB Patient: Detailed Case Analysis
by: Yovil Bagas Wiyana, et al.
Published: (2025-01-01)

Hypothyroidism in MDR-TB treatment – Rare occurrence but a major concern
by: J.S. Akshata, et al.
Published: (2015-07-01)

‘ZS-MDR-TB’ versus ‘ZR-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility
by: Ying Zhang, et al.
Published: (2012-07-01)

More is needed to end TB: commentary on the United Nations High-Level Meeting on TB
by: G. B. Migliori, et al.
Published: (2024-01-01)

Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis
by: Mahdis Cheraghi, et al.
Published: (2025-03-01)

Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.
by: Petros Isaakidis, et al.
Published: (2012-01-01)

Drug resistant TB – latest developments in epidemiology, diagnostics and management
by: Simon Tiberi, et al.
Published: (2022-11-01)

Commitment, partnerships and operational research: three priorities for 11 EMR countries to achieve TB elimination
by: M. van den Boom, et al.
Published: (2024-01-01)

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?
by: S. Tiberi, et al.
Published: (2017-12-01)

Investigating the response to COVID-19 and understanding severe TB cases: The 2022 Pulmonology TB series
by: G.B. Migliori, et al.
Published: (2022-05-01)

Influence social and healthcare support on psychiatric adverse events in MDR-TB patient
by: Reviono Reviono, et al.
Published: (2018-07-01)

RELATIONSHIP BETWEEN DETECTION OF TB AND TREATMENT OF MDR/XDR TB
by: V. Guseva, et al.
Published: (2023-08-01)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
by: Monadil H. Ali, et al.
Published: (2019-07-01)

MDR-TB TREATMENT UPDATE
by: Sean Wasserman
Published: (2023-05-01)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
by: Zhang P, et al.
Published: (2022-05-01)

Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
by: C. Zeng, et al.
Published: (2025-05-01)

Adverse Drug Reactions and Outcome Analysis of MDR Tb Patients on Dots Plus Regimen
by: Vishakha K Kapadia, et al.
Published: (2016-01-01)

TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01)

Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation
by: Dina Visca, et al.
Published: (2020-04-01)

Mathematical Model of MDR-TB and XDR-TB with Isolation and Lost to Follow-Up
by: F. B. Agusto, et al.
Published: (2015-01-01)

Occurrence and predictors of adverse events associated with linezolid in the treatment of patients with drug resistant tuberculosis and their impact on treatment outcomes
by: Abhirami V, et al.
Published: (2025-06-01)

Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for <i>ABCB1</i> and <i>SLCO1B1</i>
by: Nurul Annisa, et al.
Published: (2025-02-01)

Introducing a new series in IJTLD OPEN ‘Ending the TB epidemic’
by: H.D. Blackbourn, et al.
Published: (2025-02-01)

Disadvantage and the experience of treatment for multidrug-resistant tuberculosis (MDR-TB)
by: Holly A. Taylor, et al.
Published: (2022-12-01)

Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
by: Natalia Zaporojan, et al.
Published: (2025-07-01)

Management of MDR-TB at the University Hospital of Kinshasa
by: J.M.N. Kayembe, et al.
Published: (2014-04-01)

Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
by: Martha Van der Walt, et al.
Published: (2013-01-01)

The impact of the war in Ukraine on the prevalence of MDR/RR-TB in Poland
by: A. Nowinski, et al.
Published: (2025-01-01)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
by: Kibriti Mehari, et al.
Published: (2019-01-01)

Tuberculosis in the news: How do Portuguese media cover TB
by: F. Lopes, et al.
Published: (2018-03-01)

Tuberculosis in the news: How do Portuguese media cover TB
by: F. Lopes, et al.
Published: (2018-03-01)

TB survivors: why curing TB is sometimes not enough
by: E. Pontali, et al.
Published: (2024-12-01)

The efficacy of all-oral shorter MDR-TB and pre-XDR TB treatment in Russia
by: Anna Abramchenko, et al.
Published: (2024-12-01)

Correction: The incidence of TB and MDR-TB in pediatrics and therapeutic options: a systematic review
by: Sheetal Harichander, et al.
Published: (2022-10-01)

Treatment of MDR-TB/HIV/CMV patients under individualized regimes of antimycobacterial therapy
by: N.A. Lytvynenko, et al.
Published: (2022-12-01)

Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB
by: Chaiyasirinroje B, et al.
Published: (2012-05-01)